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Abstract 
Background: Multiparametric magnetic resonance imaging (mpMRI) of the prostate appears to 
improve prostate cancer detection, but studies comparing mpMRI to histopathology at the time of 
radical prostatectomy (RP) are lacking. This retrospective study determined the accuracy of mpMRI 
predicting Gleason score and index lesion location at the time of RP, the current gold standard for 
diagnosis. 
Methods: Between April 2013 and April 2016, a database of all men aged more than 40 years who 
underwent RP after positive transrectal ultrasound biopsy by an experienced urological surgeon was 
collated at a single regional centre. This was cross-referenced with a database of all men who had 
mpMRIs performed at a single centre and reported according to Prostate Imaging Reporting and Data 
System (PI-RADS version 1) during this period to generate a sample size of 64 men. A Spearman’s 
rho test was utilized to calculate correlation. 
Results: Median age of patients was 64 years, the median prostate-specific antigen at RP was 6.22 
ng/mL. mpMRI was positive (≥PI-RADS 3) in 85.9% of patients who underwent RP. More than 92% of 
participants had Gleason ≥7 disease. A positive relationship between mpMRI prostate PI-RADS score 
and RP cancer volume was demonstrated. An anatomical location correlation calculated in octants 
was found to be 89.1% accurate. 
Conclusion: mpMRI accurately detects prostate cancer location and severity when compared with 
gold standard histopathology at the time of RP. It thus has an important role in planning for future 
prostate biopsy and cancer treatment. 
Key words: anatomical correlation, biopsy, cancer detection, magnetic resonance imaging, prostate 
cancer. 
Introduction 
Over the last 10 years, multiparametric magnetic resonance imaging (mpMRI) of the prostate has 
emerged as a tool for the assessment and diagnosis of focal prostate cancer (PCa), especially amidst 
concerns about the accuracy of screening measures [1]. 
Interest in the accuracy of PCa assessment using mpMRI has increased in response to the low 
specificity/sensitivity of digital rectal examination [2] and issues with transrectal ultrasound (TRUS)-
guided prostate biopsy, including inadequate sampling of the anterior part of the prostate and the 
disparity between Gleason score at biopsy and pathological analysis at the time of radical 
prostatectomy (RP) [2–4]. There have been multiple recent studies published about the diagnostic 
accuracy of mpMRI, comparing preoperative MRI findings with biopsy results and cohorts of RP 
histopathology [5–7].  The aforementioned literature demonstrated that mpMRI had high sensitivity 
and high negative predictive value for detecting PCa, with limited specificity [4].  
mpMRI compares favourably with established tests such as mammography for breast cancer 
screening [8]. It has been demonstrated that men in regional areas receive PCa diagnoses later, 
receive delayed treatment and have increased morbidity and mortality when compared with men in 
metropolitan areas [9]. Therefore, it is important to explore and contextualize the role of mpMRI in a 
regional setting where risk stratification for biopsy and treatment must be performed with access and 
resource limitations in mind. The current gold standard treatment for clinically significant, non-
metastatic PCa is aimed at total removal of the gland via RP, with pelvic lymph node clearance 
[10,11]. This retrospective study utilized RP specimens to correlate Prostate Imaging Reporting and 
Data System (PI-RADS) score with definitive Gleason score and PCa volume. It also aims to 
document the accuracy of mpMRI by demonstrating anatomical concordance between mpMRI and 
RP pathology. 
 
Methods 
Study population characteristics 
Between April 2013 and April 2016, a database of all men who underwent RP by an experienced 
urological surgeon after positive biopsy was collated at a regional centre. A database of patients who 
underwent mpMRI for clinical suspicion of PCa was also collated. These databases identified 64 
patients aged ≥40 years who underwent mpMRI prostate within 18 months prior to RP. The surgeon 
used mpMRI to guide TRUS cognitive-fusion biopsy, informing the decision to proceed to RP. 
Regions of interest (ROI) appeared visible on TRUS as a hypoechoic area, which assisted targeted 
biopsy. 
Exclusion criteria included men who had their first mpMRI prostate post radiotherapy, men who had 
mpMRI but had not yet undergone RP and men with an mpMRI prostate reported by an inexperienced 
radiologist (less than 50 mpMRI previously reported). 
All procedures performed in studies involving human participants were in accordance with the ethical 
standards of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments. Ethics approval was granted by The University of Notre Dame 
Australia’s Human Research Ethics Committee. Informed consent was gained from all patients prior 
to their database inclusion. 
Study protocol 
mpMRIs were performed at a single centre using the Discovery MR750w 3.0T (GE Healthcare, 
Chicago, IL, USA), 3-Tesla magnet and a standardized protocol as per published mpMRI prostate 
studies [1,5]. In RP-naïve men, a cognitive-fusion biopsy with 16–24 cores was utilized to obtain a 
Gleason score. Indications for RP adhered to a definition of clinically significant PCa. Significant PCa 
was defined as either Gleason score ≥7, PCa volume >0.5 cm3 at RP specimen analysis or extra-
prostatic extension, in line with current literature [2,4,11].  
MRI was prospectively anatomically correlated to RP in octants. The data collectors entering mpMRI 
and RP anatomic locations were blinded to prevent bias. An index lesion (IL) based on size was 
analysed on a per-patient basis for apparent diffusion coefficient and RP specimen. RP 
histopathology was performed at two regional centres as per established World Health Organization 
(WHO) reporting guidelines. 
Reporting protocol 
Two radiologists (ID and NS) reported mpMRIs independently as ordered by the clinician (SS). Each 
radiologist had reported more than 50 prior prostate MRIs. Standard PI-RADS version 1 was used. 
Radiologists were given clinical data including PSA, digital rectal examination and family history.  
Standardized PI-RADS is on a five-point scale, which describes clinically significant PCa; 1, extremely 
unlikely; 2, unlikely; 3, equivocal; 4, likely or 5, extremely likely [12]. Using objective criteria, ROI were 
assigned a score for each parameter including T2-weighted imaging (T2WI), dynamic contrast-
enhanced imaging and diffusion weighted imaging. For the purpose of the study, positivity was 
defined as PI-RADS ≥3, in line with other mpMRI prostate studies [3,4,13–16].  The study’s primary 
end point was to demonstrate a correlation between PI-RADS and Gleason score/PCa volume.  
A blinded investigator correlated location according to retrospective mpMRI radiology reports and 
pathology reports. MRI ILs were retrospectively defined by the investigator as lesions with the highest 
PI-RADS score. The prostate was divided into octants at histopathology to characterize IL. mpMRI ILs 
were described in octants in order to determine correlation between mpMRI and RP specimen. 
Secondary lesions were reported descriptively. 
Statistical analysis 
Statistics were performed using Microsoft Excel Professional Plus 2013 (Windows 10 Enterprise; 
Microsoft, Redmond, WA, USA) and IBM SPSS version 22 (IBM, Armonk, NY, USA). Tests were two-
tailed and a p-value of <0.05 was considered significant. A Spearman’s rank correlation was utilized 
to determine the correlation between PI-RADS and Gleason score at TRUS biopsy and RP, and PI-
RADS and PCa volume at RP given the distribution of the data. A Kruskal–Wallis H-test was used to 
assess statistical difference between PI-RAD categories and mean PCa volume. 
 
Results 
Baseline characteristics 
The median age of the study population was 64 (35–79) years, and 92% of participants had at least 
Gleason 7 disease. The median PSA at the time of surgery was 6.22 ng/mL. Seventy-five percent of 
patients had a volume of PCa >0.5 cm3 at RP histopathology.  
Biopsy results  
There was 75% correlation between cognitive-fusion biopsy Gleason score and RP specimen 
Gleason score. Of the 16 patients whose Gleason scores did not correlate, 13 were upgraded from 
biopsy to RP. This corresponded to a 20.3% rate of Gleason score upgrade from biopsy to RP. Table 
1 shows a cross-tabulation of the distribution of biopsy Gleason results within PI-RADS score 
categories.  
RP specimen results 
Sixty-four patients underwent RP after mpMRI and TRUS biopsy. Table 1 demonstrates the 
distribution of Gleason scores at the time of RP specimen histopathology and their percentage within 
each PI-RADS score category. The five patients who were found to have Gleason 6 disease were all 
found to have PCa volumes ≥0.5 cm3.  
 
Table 1: Gleason score at biopsy and at radical prostatectomy according to PI-RADS  
Gleason Score 
PI-RADS [n (%)] 
2 3 4 5 
At biopsy 
6 3 (33.3) 1 (9.1) 4 (25.0) 8 (28.6) 
7 4 (44.4) 9 (81.8) 12 (75.0) 15 (53.6) 
8 2 (22.2) 1 (9.1) 0 2 (7.1) 
9 0 0 0 3 (10.7) 
At radical 
prostatectomy 
6 2 (22.2) 1 (9.1) 0 2 (7.1) 
7 5 (55.6) 10 (90.9) 16 (100) 22 (78.6) 
8 2 (22.2) 0 0 1 (3.6) 
9 0 0 0 3 (10.7) 
 
Forty-six (71.9%) patients had PCa volumes ≥0.5 cm3 at the time of RP specimen analysis. Figure 1 
demonstrates the relationship between PCa and volume at RP when compared with mpMRI PIRADS. 
Significant PCa (volume ≥0.5 cm3) was found in 55.6% of patients reported as PI-RADS 2, 54.5% of 
patients reported as PIRADS 3, 87.5% of patients reported as PI-RADS 4 and 82.1% of patients 
reported as PI-RADS 5. 
There was no correlation between PI-RADS and Gleason scores; however, there was a positive 
correlation between PI-RADS score and PCa volume (Spearman’s ρ = 0.356, p = 0.004). Gleason 
score was also positively associated with PCa volume (Spearman’s ρ = 0.347, p = 0.005). 
Cancer volume increased with increasing PI-RADS score (p = 0.018). Mean cancer volume at the 
time of RP histopathology was reported as 0.79 cm3 for PI-RADS 2 PCa, 0.95 cm3 for PIRADS 3 
PCa, 1.87 cm3 for PI-RADS 4 PCa and 2.47 cm3 for PIRADS 5 PCa. 
There were nine patients whose PCa was reported as insignificant (PI-RADS 2), of whom seven were 
found to have ≥Gleason 7 disease at RP. Fifty-five patients had significant disease on mpMRI (≥PI-
RADS 3), three of whom had Gleason 6 disease reported at RP. 
 
 
Figure 1: Prostate cancer volume versus Prostate Imaging Reporting and Data System (PI-RADS) 
score. 
 
Correlation location 
Fifty-seven (89.1%) patients had an IL described on mpMRI that corresponded with the IL reported at 
RP. Table 2 describes features of ILs on mpMRI that did not correspond with IL at RP. Seven 
significant PCas found at RP were not identified on mpMRI (Table S1). The majority (5/7) of 
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significant PCa missed was intermediate risk with Gleason score 3 + 4 = 7 (n = 3) or Gleason 4 + 3 = 
7 (n = 1). Two patients were found to have Gleason 8 disease at the time of RP. Both patients had an 
mpMRI demonstrating diffuse low-grade signal abnormality, attributed to benign glandular 
hyperplasia. 
 
Table 2: MRI IL versus radical prostatectomy IL locations 
Patient No. MRI IL 
Other regions 
MRI 
RP IL 
Other regions 
RP 
4 
Left anterolateral 
mid 
Left anterior 
apex 
Postero-lateral right 
Left posterior 
apex 
10 Left posterior Right PZ 
Right posterior 
peripheral 
 
30 
Diffuse bilateral 
non-specific 
change 
- Posterior–left and right -Right PZ 
33 Central bilateral Left PZ 
Apex, peripheral zones 
bilaterally 
 
40 
Minor left and right 
change 
 
Multifocal cancer in all 
quadrants, largest 
volume in right PZ 
 
45 
Left base with 
seminal vesical 
invasion 
 
Left and right apex, no 
seminal vesical invasion 
 
56 
Diffuse central 
gland abnormality 
  
Extensive bilaterally in 
PZ 
Foci in left and 
right posterior 
quadrants 
IL - index lesion; MRI – magnetic resonance imaging; PZ – peripheral zone 
 
Discussion 
Accurately sampling the prostate during biopsy has become increasingly important amidst concerns 
that men are presenting later and with more advanced disease as a result of the recommendations 
against routine PSA screening released in 2012 [1].  
mpMRI prostate has been widely adopted by Australian urologists to characterize PCa prior to initial 
biopsy, with approximately one in five urologists ordering pre-biopsy MRI in 2015 [17]. Its use has 
been promoted by the Urological Society of Australia and New Zealand (USANZ) to aid cognitive-
fusion or in-gantry biopsy for active surveillance of low-risk disease and to stage newly diagnosed 
PCa [18]. USANZ lodged an application to the Medicare Benefits Schedule for funding both cognitive-
fusion and in-gantry MRI biopsies which was only recently opposed in April 2017 [19].  
In this study, the primary surgeon utilized mpMRI to guide cognitive-fusion TRUS biopsy. This is a 
widely accessible technology, which allows the surgeon to prioritize the ROI pre-identified on mpMRI.  
Our study demonstrated a significant positive correlation between PI-RADS score and PCa volume at 
the time of RP. Tumour volume was not assessed on MRI in this patient group but the PI-RADS score 
itself contains a relevant quantitative component, with increasing PI-RADS score indicating increasing 
capsular contact by the PCa [8].  
There are limited published studies reporting anatomical correlation between lesions with a high PI-
RADS and IL at RP histopathology [1,15,20]. One retrospective study comparing cognitive-fusion 
biopsy of 63 patients with robotic RP whole-mount pathology found MRI was anatomically accurate in 
73% of cases [21]. Patel et al. [21] mapped the prostate into 24 segments on MRI and histopathology 
to correlate ILs, which likely accounts for its decreased accuracy compared with our study, despite a 
similar sample size. Thompson et al. compared ROIs in the transperineal template-guided mapping 
biopsy and whole-mount RP histopathology of 109 men with an 18-segment prostate map and found 
97% anatomical concordance, of which 86.5% matched exactly and 13.5% matched but had separate 
missed significant PCa on MRI [16]. This breakdown of results would have been a useful addition to 
the data collected by our investigators, but we were unable to confidently correlate the results, given 
we retrospectively defined the MRI IL. Whole-mount pathology was not available to us at our regional 
pathology provider. In the current study, the prostate was divided into octants in order to describe 
lesions, as this is how they were reported at the time of histopathological analysis. 
PCa is the only solid organ malignancy that is diagnosed by blind biopsy, i.e. without visualization of 
the tumour [22]. Without image guidance, systematic TRUS biopsy inadequately samples lesions in 
the apex, anterior and midline of the prostate [23]. Attempts to increase sampling with additional cores 
can increase morbidity from bleeding [24] and lower urinary tract symptoms and infection, with 
readmission rates as high as 2% [3,25]. The inaccuracy of blind biopsy is evident in the frequent 
disparity between biopsy Gleason score at biopsy when compared to RP, with a recent study of 5339 
cases finding only 54.5% concordance [26]. 
Techniques proposed to increase accuracy include increasing biopsy cores (16, 24, 28 or 36), MRI 
prior to standard TRUS biopsy with additional targeted cores and ultrasound/MRI (cognitive) fusion 
biopsies, designed to improve the specificity of the lesions targeted [8,16]. There is no consensus on 
the optimal core number for PCa detection without an increase in morbidity, which ranges between 12 
and 36 for some template-mapped and perineal biopsy protocols [7,15,25,27]. The primary operator 
has reduced from an 18–24 core biopsy protocol to an aforementioned 12 core with four additional 
cores in mpMRI identified ROIs. 
This research adds to the body of evidence that IL can be identified on prostate mpMRI prior to TRUS 
biopsy and RP in the majority of men. The ability of mpMRI to accurately detect the anatomical 
location of PCa ILs is important for cognitive-fusion biopsy, where the urologist uses ‘visual 
registration’ to aim biopsy cores at known mpMRI targets. This technique is simple, inexpensive and 
does not require additional equipment [28]. 89.1% of patients’ IL was correctly identified on mpMRI 
prior to TRUS biopsy and RP, which supports the validity of targeted cognitive fusion biopsy by an 
experienced operator. 
Cognitive-fusion biopsy is more readily available in regional centres, given the absence of 
transperineal biopsy mapping and in-gantry biopsy techniques. Utilizing this technique with 12–18 
cores is less time-consuming, less costly and involves a reduced general anaesthesia time for the 
patient when compared with techniques aforementioned [23,25]. Whilst access to specialist and 
radiology services is improving in Australian regional centres, there is a recognized discrepancy 
between Medicare-funded services, health workforce and individual health status between rural and 
metropolitan areas [28].  
There is minimal extra requirement of urologists, radiographers or local health services when utilizing 
cognitive-fusion biopsy. Ultrasound-MRI fusion and in-gantry biopsy techniques require more ancillary 
staff including appropriately trained radiographers and registered nurses. Additionally, the Medical 
Services Advisory Committee costed these three procedures at $925.72, $1149.72 and $2375.11, 
respectively [19]. Cognitive-fusion biopsy is a sensible option to reduce the human and financial cost 
whilst maintaining accuracy. 
There is ongoing debate about the reference standard to which mpMRI is compared [28]. A 
systematic review found that ‘various authors advocate comparing MRI with transrectal biopsy, TPB 
or prostatectomy specimens’ but concluded that even studies which compared both biopsy and RP 
specimens to MRI produced similar results, a high negative predictive value of MRI specimens 
[2,4,14–16,18,24,28]. Transperineal biopsy can provide a more comprehensive sample of the prostate 
for comparison [24]. This was a limitation of our study; however, it is not currently available in regional 
New South Wales centres. 
In this study, there was no significant correlation between PIRADS and Gleason score at RP, likely 
due to the skew of our small sample size towards Gleason 7 disease, reducing the spread at the 
higher Gleason range. However, the characteristics of patients who underwent RP were similar to 
other studies conducted in tertiary centres [4,15,17,18,20]. 
Four patients who had Gleason ≥7 with volumes >0.5 cm3 were reported as PI-RADS 2 on initial 
mpMRI. A limitation of this retrospective study was the presence of sample bias. All patients in our 
study population had significant PCa, thus a high false negative rate. This indicates that although 
mpMRI enables the targeted sampling of potential PCa focus, it is not a reliable substitute for initial 
biopsy. 
At the time of database collation, PI-RADS version 1 was the most current reporting system [20]. PI-
RADS version 2 (2015) places greater emphasis on T2WI and DWI for PCa detection in the transition 
peripheral zones and places less emphasis on DCE [7,17] which was weakly correlated in this study 
compared with T2WI and DWI. Our findings support the changes made to the PI-RADS reporting 
score. 
 
Conclusions 
mpMRI was able to detect clinically significant PCa with greater accuracy for PCa volume than 
Gleason score. Location correlation between mpMRI IL and RP specimen tumour focus demonstrated 
high accuracy in a small sample size. This study supports the use of cognitive-fusion biopsy, 
especially in regional centres with limited access to in-bore MRI or MRI-ultrasound fusion technology. 
Further prospective studies comparing mpMRI cognitive-fusion biopsy with RP specimens are needed 
to support more widespread use of mpMRI-targeted biopsy in clinical practice. 
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Table S1: Features of significant prostate cancer missed on mpMRI 
Patient 
Number 
PI-RADS  
Score 
Gleason 
Score 
Volume 
(cm3) 
PSA  
(ng/mL)  
3 2 7 0.1 2.8 
12 2 7 0.7 6.4 
45 2 8 2.0 7.0 
50 2 7 0.2 4.8 
52 2 7 0.8 6.6 
55 2 8 0.8 8.1 
64 2 7 0.2 4.8 
 
 
